Hope S. Rugo, MD, FASCO

EMBER-3 trial findings position imlunestrant monotherapy or in combination with abemaciclib as a promising, safe and effective oral therapeutic option for treating estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Read More ›

Elacestrant in combination with ribociclib or everolimus demonstrates promising efficacy and manageable safety in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who experienced disease progression after endocrine therapy plus CDK4/6 inhibitors, Read More ›

The SERENA-6 trial reveals camizestrant's potential to improve outcomes in hormone receptor (HR)-positive, HER2-negative breast cancer by utilizing circulating tumor DNA (ctDNA)-guided therapy towards ESR1 mutations before disease progression. Read More ›

Patient-reported outcomes from EMBER-3 demonstrate that imlunestrant improves global health status/quality of life and physical function in patients with ESR1 mutations in estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Read More ›